Iambic Therapeutics Inc. shares soared 16% in its trading debut after the clinical-stage cancer drugmaker and technology firm raised $150 million in a US initial public offering.
Mostramos la idea principal publicamente. Crea una cuenta gratis para seguir leyendo el articulo completo, guardarlo, comentarlo y conectarlo con contexto de mercados y OSINT.